title: Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6.
authors.affiliation: Pacific Health Foundation, San Jose, CA, USA.
authors.forename: Khoa D
authors.initials: KD
authors.lastname: Lam
authors.forename: Huy N
authors.initials: HN
authors.lastname: Trinh
authors.forename: Son T
authors.initials: ST
authors.lastname: Do
authors.forename: Thuan T
authors.initials: TT
authors.lastname: Nguyen
authors.forename: Ruel T
authors.initials: RT
authors.lastname: Garcia
authors.forename: Tuan
authors.initials: T
authors.lastname: Nguyen
authors.forename: Quang Q
authors.initials: QQ
authors.lastname: Phan
authors.forename: Huy A
authors.initials: HA
authors.lastname: Nguyen
authors.forename: Khanh K
authors.initials: KK
authors.lastname: Nguyen
authors.forename: Long H
authors.initials: LH
authors.lastname: Nguyen
authors.forename: Mindie H
authors.initials: MH
authors.lastname: Nguyen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002140:California; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012449:Safety; D013781:Texas; D019562:Viral Load; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a